Prospective evAluatIon foR inhalation devices in Greek patients with COPD and asthma : The PAIR study
Copyright © 2019. Published by Elsevier Ltd..
INTRODUCTION: Chronic obstructive pulmonary disease (COPD) and asthma remain a major health burden. Adherence to inhaled therapy is critical in order to optimize treatment effectiveness. Properly designed questionnaires can assess patients' satisfaction with their inhaler devices.
PATIENTS AND METHODS: A total of 766 patients with COPD, asthma or Asthma-COPD Overlap (ACO) were initially enrolled. During their first visit, patients were classified into three groups (Diskus™, Elpenhaler®, Turbuhaler®). Patients completed the FSI-10 questionnaire on Day 0 and Day 60. Test-retest reliability was evaluated.
RESULTS: A total of 705 patients completed the study. FSI-10 questionnaire had good test-retest reliability (Total Intraclass Correlation Coefficient: 0.86). All dry powder inhaler (DPIs) yielded satisfactory results. Median score of FSI-10 questionnaire in first visit (FSI-10-I) was significantly higher for patients receiving Elpenhaler® (45, 95% CI: 44 to 46) than patients receiving Diskus™ (42, 95% CI: 41 to 43) and Turbuhaler® (42, 95% CI: 41 to 43) (p < 0.001). Accordingly, median score of FSI-10 questionnaire in the final visit (FSI-10-II) was significantly higher for patients receiving Elpenhaler® (46, 95% CI: 45 to 47) than patients receiving Diskus™ (42, 95% CI: 41 to 43) and Turbuhaler® (43, 95% CI: 42 to 44) (p < 0.001).
CONCLUSION: FSI-10 questionnaire had good test-retest reliability and thus can be used in the follow-up of patients with COPD, asthma and ACO. All DPIs were highly acceptable among all study groups. Elpenhaler® achieved significantly higher ratings than Diskus™ and Turbuhaler® in FSI-10 score and presented higher preference among patients with obstructive lung diseases.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:60 |
|---|---|
| Enthalten in: |
Pulmonary pharmacology & therapeutics - 60(2020) vom: 15. Feb., Seite 101882 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 12.02.2021 Date Revised 12.02.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.pupt.2019.101882 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM304812919 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM304812919 | ||
| 003 | DE-627 | ||
| 005 | 20231225115806.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.pupt.2019.101882 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1016.xml |
| 035 | |a (DE-627)NLM304812919 | ||
| 035 | |a (NLM)31881275 | ||
| 035 | |a (PII)S1094-5539(19)30317-7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Karampitsakos, Theodoros |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Prospective evAluatIon foR inhalation devices in Greek patients with COPD and asthma |b The PAIR study |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 12.02.2021 | ||
| 500 | |a Date Revised 12.02.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2019. Published by Elsevier Ltd. | ||
| 520 | |a INTRODUCTION: Chronic obstructive pulmonary disease (COPD) and asthma remain a major health burden. Adherence to inhaled therapy is critical in order to optimize treatment effectiveness. Properly designed questionnaires can assess patients' satisfaction with their inhaler devices | ||
| 520 | |a PATIENTS AND METHODS: A total of 766 patients with COPD, asthma or Asthma-COPD Overlap (ACO) were initially enrolled. During their first visit, patients were classified into three groups (Diskus™, Elpenhaler®, Turbuhaler®). Patients completed the FSI-10 questionnaire on Day 0 and Day 60. Test-retest reliability was evaluated | ||
| 520 | |a RESULTS: A total of 705 patients completed the study. FSI-10 questionnaire had good test-retest reliability (Total Intraclass Correlation Coefficient: 0.86). All dry powder inhaler (DPIs) yielded satisfactory results. Median score of FSI-10 questionnaire in first visit (FSI-10-I) was significantly higher for patients receiving Elpenhaler® (45, 95% CI: 44 to 46) than patients receiving Diskus™ (42, 95% CI: 41 to 43) and Turbuhaler® (42, 95% CI: 41 to 43) (p < 0.001). Accordingly, median score of FSI-10 questionnaire in the final visit (FSI-10-II) was significantly higher for patients receiving Elpenhaler® (46, 95% CI: 45 to 47) than patients receiving Diskus™ (42, 95% CI: 41 to 43) and Turbuhaler® (43, 95% CI: 42 to 44) (p < 0.001) | ||
| 520 | |a CONCLUSION: FSI-10 questionnaire had good test-retest reliability and thus can be used in the follow-up of patients with COPD, asthma and ACO. All DPIs were highly acceptable among all study groups. Elpenhaler® achieved significantly higher ratings than Diskus™ and Turbuhaler® in FSI-10 score and presented higher preference among patients with obstructive lung diseases | ||
| 650 | 4 | |a Clinical Trial | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Adherence | |
| 650 | 4 | |a Asthma | |
| 650 | 4 | |a Chronic obstructive pulmonary disease | |
| 650 | 4 | |a Questionnaire | |
| 650 | 4 | |a Satisfaction | |
| 650 | 4 | |a Test-retest reliability | |
| 650 | 7 | |a Anti-Asthmatic Agents |2 NLM | |
| 700 | 1 | |a Hillas, Georgios |e verfasserin |4 aut | |
| 700 | 1 | |a Zervas, Eleftherios |e verfasserin |4 aut | |
| 700 | 1 | |a Bakakos, Petros |e verfasserin |4 aut | |
| 700 | 1 | |a Stratakos, Grigorios |e verfasserin |4 aut | |
| 700 | 1 | |a Dimakou, Katerina |e verfasserin |4 aut | |
| 700 | 1 | |a Manali, Efrosyni |e verfasserin |4 aut | |
| 700 | 1 | |a Bouros, Demosthenes |e verfasserin |4 aut | |
| 700 | 1 | |a Papiris, Spyridon |e verfasserin |4 aut | |
| 700 | 1 | |a Tzouvelekis, Argyrios |e verfasserin |4 aut | |
| 700 | 0 | |a PAIR study investigators |e verfasserin |4 aut | |
| 700 | 1 | |a Adamidis, Vasilios |e investigator |4 oth | |
| 700 | 1 | |a Adamou, Helen |e investigator |4 oth | |
| 700 | 1 | |a Agelidis, Xenophon |e investigator |4 oth | |
| 700 | 1 | |a Albantakis, Konstantinos |e investigator |4 oth | |
| 700 | 1 | |a Anaplioti, Aikaterini |e investigator |4 oth | |
| 700 | 1 | |a Babalis, Christos |e investigator |4 oth | |
| 700 | 1 | |a Balasoulis, George |e investigator |4 oth | |
| 700 | 1 | |a Christou, Konstantinos |e investigator |4 oth | |
| 700 | 1 | |a Filippidou, Christina |e investigator |4 oth | |
| 700 | 1 | |a Fothiantakis, Emmanuel |e investigator |4 oth | |
| 700 | 1 | |a Gavriilidou, Anna |e investigator |4 oth | |
| 700 | 1 | |a Goulia, Hypakoe |e investigator |4 oth | |
| 700 | 1 | |a Houliara, Konstantina |e investigator |4 oth | |
| 700 | 1 | |a Kainis, Elias |e investigator |4 oth | |
| 700 | 1 | |a Kakavelas, Paschalis |e investigator |4 oth | |
| 700 | 1 | |a Kalampoka, Dionysia |e investigator |4 oth | |
| 700 | 1 | |a Kalfountzos, George |e investigator |4 oth | |
| 700 | 1 | |a Kammenidis, Savvas |e investigator |4 oth | |
| 700 | 1 | |a Karkanis, Konstantinos |e investigator |4 oth | |
| 700 | 1 | |a Karyanou, Eugenia |e investigator |4 oth | |
| 700 | 1 | |a Katertzi, Maria |e investigator |4 oth | |
| 700 | 1 | |a Kopanakis, Antonios |e investigator |4 oth | |
| 700 | 1 | |a Kotantoula, Georgia |e investigator |4 oth | |
| 700 | 1 | |a Liapikou, Adamantia |e investigator |4 oth | |
| 700 | 1 | |a Manali, Efrosyni |e investigator |4 oth | |
| 700 | 1 | |a Manolakoglou, Nikolaos |e investigator |4 oth | |
| 700 | 1 | |a Marosis, Konstantinos |e investigator |4 oth | |
| 700 | 1 | |a Michailidou, Demetrios |e investigator |4 oth | |
| 700 | 1 | |a Oikonomides, Peter |e investigator |4 oth | |
| 700 | 1 | |a Palamidas, Anastasios |e investigator |4 oth | |
| 700 | 1 | |a Papandreou, Athanasios |e investigator |4 oth | |
| 700 | 1 | |a Pataka, Athanasia |e investigator |4 oth | |
| 700 | 1 | |a Pitenis, Athanasios |e investigator |4 oth | |
| 700 | 1 | |a Porpodis, Konstantinos |e investigator |4 oth | |
| 700 | 1 | |a Stratis, Andreas |e investigator |4 oth | |
| 700 | 1 | |a Terovitou, Chrysavgi |e investigator |4 oth | |
| 700 | 1 | |a Trikrika, Evangelia |e investigator |4 oth | |
| 700 | 1 | |a Tsiaga, Pashalia |e investigator |4 oth | |
| 700 | 1 | |a Tsiounta, Theodora |e investigator |4 oth | |
| 700 | 1 | |a Vlachou, Athina |e investigator |4 oth | |
| 700 | 1 | |a Zois, Dimitrios |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Pulmonary pharmacology & therapeutics |d 1997 |g 60(2020) vom: 15. Feb., Seite 101882 |w (DE-627)NLM092899625 |x 1522-9629 |7 nnns |
| 773 | 1 | 8 | |g volume:60 |g year:2020 |g day:15 |g month:02 |g pages:101882 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.pupt.2019.101882 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 60 |j 2020 |b 15 |c 02 |h 101882 | ||